European Journal of Internal Medicine
Volume 18, Issue 6 , Pages 496-500 , October 2007

Comparison of 1- and 2-week pantoprazole-based triple therapies in clarithromycin-sensitive and resistant cases

  • Ahmet Aydin

      Affiliations

    • Ege University Medical School, Department of Gastroenterology, Izmir, Turkey
    • ,
  • Goktug Onder

      Affiliations

    • Ege University Medical School, Department of Gastroenterology, Izmir, Turkey
    • ,
  • Ulus Akarca

      Affiliations

    • Ege University Medical School, Department of Gastroenterology, Izmir, Turkey
    • ,
  • Fatih Tekin

      Affiliations

    • Ege University Medical School, Department of Gastroenterology, Izmir, Turkey
    • Corresponding Author InformationCorresponding author. Ege Universitesi Tip Fakultesi, Gastroenteroloji Bilim Dali, Bornova 35100, Izmir, Turkey. Tel.: +90 232 3903476; fax: +90 232 3427764.
    • ,
  • Muge Tuncyurek

      Affiliations

    • Ege University Medical School, Department of Pathology, Izmir, Turkey
    • ,
  • Tankut Ilter

      Affiliations

    • Ege University Medical School, Department of Gastroenterology, Izmir, Turkey

Received 13 August 2006 ,Revised 25 November 2006 ,Accepted 9 February 2007.

References 

  1. Malfertheiner P, Megraud F, O'Morain C, Hungin AP, Jones R, Axon A, et al. Current concepts in the management of H pylori infection the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther. 2002;16:167–180
  2. Tankovic J, Lamarque D, Lascols C, Soussy CJ, Delchier JC. Clarithromycin resistance of Helicobacter pylori has a major impact on the efficacy of the omeprazole–amoxicillin–clarithromycin therapy. Pathol Biol. 2001;49:528–533
  3. Calvet X, Garcia N, Lopez T, Gispert JP. A metaanalysis of short versus long therapy with a proton pomp inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther. 2000;14:603–609
  4. Kadayýfci A, Buyukhatipoglu H, Koruk M, Simsek I. Türkiye'de H pylori eradikasyonunda PPI, Amoksisilin ve Klaritromisin tedavisinin etkinligi; Meta-analiz. Turk J Gastroenterol. 2004;15(suppl 1):5
  5. Meyer JM, Silliman NP, Wang W, Siepman NY. Risk factors for Helicobacter pylori resistance in the United States: the SHARP study, 1993–1999. Ann Intern Med. 2002;136:13–24
  6. Houben MHMG, van de Beek D, Hensen EF, Craen AJ, Rauws EA, Tytgat GN. A systematic review of Helicobacter pylori eradication therapy, the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther. 1999;13:1047–1056
  7. Broutet N, Tchamgoue S, Pereira E, Lamouliatte H, Salamon R, Megraud F. Risk factors for failure of Helicobacter pylori therapy—results of an individual data analysis of 2751 patients. Aliment Pharmacol Ther. 2003;17:99–109
  8. Taylor DE, Ge Z, Purych D, Lo T, Hiratsuka K. Cloning and sequence analysis of two copies of a 23S rRNA gene from Helicobacter pylori and association of clarithromycin resistance with 23S rRNA mutations. Antimicrob Agents Chemother. 1997;41:2621–2628
  9. Tomb JF, White O, Kerlavage AR, Clayton RA, Sutton GG, Fleischmann RD, et al. The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature. 1997;388:539–547
  10. Hulten K, Gibreel A, Skold O, Engstrand L. Macrolide resistance in Helicobacter pylori: mechanism and stability in strains from clarithromycin-treated patients. Antimicrob Agents Chemother. 1997;41:2550–2553
  11. Occhialini A, Urdaci M, Doucet-Populaire F, Bebear CM, Lamouliatte H, Megraud F. Macrolide resistance in Helicobacter pylori: rapid detection of point mutations and assays of macrolide binding to ribosomes. Antimicrob Agents Chemother. 1997;41:2724–2728
  12. Stone GG, Shortridge D, Flamm RK, Versalovic J, Beyer J, Idler K, et al. Identification of a 23S rRNA gene mutation in clarithromycin-resistant Helicobacter pylori. Helicobacter. 1996;1:227–228
  13. Versalovic J, Osato MS, Spakovsky K, Dore MP, Reddy R, Stone GG, et al. Point mutations in the 23S rRNA gene of Helicobacter pylori associated with different levels of clarithromycin resistance. J Antimicrob Chemother. 1996;40:283–286
  14. Khan R, Nahar S, Sultana J, Ahmad MM, Rahman M. T2182C mutation in 23S rRNA is associated with clarithromycin resistance in Helicobacter pylori isolates obtained in Bangladesh. Antimicrob Agents Chemother. 2004;48:3567–3569
  15. van Doorn LJ, Glupczynski Y, Kusters JG, Mégraud F, Midolo P, Maggi-Solcà N, et al. Accurate prediction of macrolide resistance in Helicobacter pylori by a PCR line probe assay for detection of mutations in the 23S rRNA gene: multicenter validation study. Antimicrob Agents Chemother. 2001;45:1500–1504
  16. Versalovic J, Shortridge D, Kibler K, Griffy MV, Beyer J, Flamm RK, et al. Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori. Antimicrob Agents Chemother. 1996;40:477–480
  17. McLoughlin R, Racz I, Buckley M, O'Connor HJ, O'Morain C. Therapy of Helicobacter pylori. Helicobacter. 2004;9(Suppl 1):S42–S48
  18. Thyagarajan SP, Ray P, Das BK, Ayyagari A, Khan AA, Dharmalingam S, et al. Geographical difference in antimicrobial resistance pattern of Helicobacter pylori clinical isolates from Indian patients: multicentric study. J Gastroenterol Hepatol. 2003;18:1373–1378
  19. Vasquez A, Valdez Y, Gilman RH, McDonald JJ, Westblom TU, Berg D, et al. Metronidazole and clarithromycin resistance in Helicobacter pylori determined by measuring MICs of antimicrobial agents in color indicator egg yolk agar in a miniwell format. Clin Microbiol. 1996;34:1232–1234
  20. Vakil N, Hahn B, McSorley D. Clarithromycin-resistant Helicobacter pylori in patients with duodenal ulcer in the United States. Am J Gastroenterol. 1998;93:1432–1435
  21. Debets-Ossenkopp YJ, Herscheid AJ, Pot RG, Kuipers EJ, Kusters JG, Vandenbroucke-Grauls CM. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin, tetracycline and trovafloxacin in the Netherlands. J Antimicrob Chemother. 1999;43:511–515
  22. Crone J, Granditsch G, Huber WD, Binder C, Innerhofer A, Amann G, et al. Helicobacter pylori in children and adolescents: increase of primary clarithromycin resistance, 1997–2000. J Pediatr Gastroenterol Nutr. 2003;36:368–371
  23. Cabrita J, Oleastro M, Matos R, Manhente A, Cabral J, Barros R, et al. Features and trends in Helicobacter pylori antibiotic resistance in Lisbon area, Portugal (1990–1999). J Antimicrob Chemother. 2000;46:1029–1031
  24. Kato M, Yamaoka Y, Kim JJ, Reddy R, Asaka M, Kashima K, et al. Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan. Antimicrob Agents Chemother. 2000;44:2214–2216
  25. Eun CS, Han DS, Park YJ, Jeon YC, Hahm JS, Kim KS, et al. Changing pattern of anti-microbial resistance of Helicobacter pylori in Korean patients with peptic ulcer diseases. J Gastroenterol. 2003;38:436–441
  26. Boyanova L, Mentis A, Gubina M, Rozynek E, Gosciniak G, Kalenic S, et al. The status of antimicrobial resistance of Helicobacter pylori in Eastern Europa. Clin Microbiol Infect. 2002;8:388–396
  27. Aydin A, Buke C, Akiner C, Karasu Z, Demir A, Gunhan C. Helicobacter pylori nin klaritromisine duyarliligi azaliyor mu. Turk J Gastroenterol. 1998;9(suppl 1):55
  28. Onder GF, Aydin A, Akarca US, Ozutemiz O, Ilter T. Ulkemizde Helicobacter pylori nin klaritromisine direncinin real-time PCR yontemi ile arastirilmasi. Turk J Gastroenterol. 2004;15(suppl 1):40
  29. Calvet X, Gene E, Lopez T, Gispert JP. What is the optimal length of proton pump inhibitor-based triple therapies for H pylori? A cost-effectiveness analysis. Aliment Pharmacol Ther. 2001;15:1067–1076
  30. Gisbert JP, Khorrami S, Calvet X, Pajares JM. Pantoprazole based therapies in Helicobacter pylori eradication: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2004;16:89–99
  31. Louw JA, van Rensburg CJ, Hanslo D, Grundlings HD, Girdwood AH, Marks IN. Two-week course of pantoprazole combined with 1 week of amoxycillin and clarithromycin is effective in Helicobacter pylori eradication and duodenal ulcer healing. Aliment Pharmacol Ther. 1998;12:545–550

PII: S0953-6205(07)00148-3

doi: 10.1016/j.ejim.2007.02.018

European Journal of Internal Medicine
Volume 18, Issue 6 , Pages 496-500 , October 2007

Article Tools